Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model

Int J Cancer. 2001 Feb 15;91(4):529-37. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1074>3.0.co;2-o.

Abstract

Tumors escape immune-mediated rejection by a variety of mechanisms during tumor progression. The elucidation of these mechanisms in vivo suffers from a lack of suitable models of spontaneous tumor formation escaping active specific immunotherapy (ASI). In a rat neu transgenic (rNeu-TG) mouse model of spontaneous breast tumor formation, we showed that rNeu-TG mice developed late escape tumors despite the presence of a persistent rNeu-specific immune response after ASI. Cell suspensions derived from these escape tumors grew in vaccinated tumor-free mice, whereas injected spontaneous tumor cells were rejected. Escape tumors retained rNeu or MHC class I expression but significantly upregulated Fas (CD95, Apo-1) ligand. We further demonstrated that Fas-L on escape tumor cells correlated with apoptosis of infiltrating T lymphocytes. Thus, our results provide evidence that spontaneous breast tumors upregulate Fas-L expression after vaccination that may promote tumor escape in vivo after ASI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells
  • Animals
  • Apoptosis
  • Breast Neoplasms / immunology
  • Breast Neoplasms / metabolism
  • Cancer Vaccines*
  • Cell Separation
  • Fas Ligand Protein
  • Female
  • Flow Cytometry
  • Genes, MHC Class I / genetics
  • Immunohistochemistry
  • Lymphocytes / immunology
  • Lymphocytes / metabolism
  • Mammary Neoplasms, Animal / metabolism
  • Mammary Neoplasms, Animal / pathology
  • Membrane Glycoproteins / biosynthesis*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Transgenic
  • Neoplasm Transplantation
  • Neoplasms, Experimental / metabolism
  • Neoplasms, Experimental / pathology
  • Polymerase Chain Reaction
  • Rats
  • Receptor, ErbB-2 / genetics
  • T-Lymphocytes / metabolism
  • Time Factors
  • Up-Regulation

Substances

  • Cancer Vaccines
  • Fas Ligand Protein
  • Fasl protein, mouse
  • Faslg protein, rat
  • Membrane Glycoproteins
  • Receptor, ErbB-2